Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
527808
Thousand yenWording
Conditional
How definitive the wording is.Results for this period
Third quarter1 January 2026–30 September 2026Non-consolidated (individual)Japanese GAAPNet Sales527¥ million
Operating profit-1,104¥ million
Ordinary income-1,112¥ million
Net income attributable to owners of the parent-1,115¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Net income per share−¥38.01
Financial position at period-end
Total assets3,752¥ million
of which net assets 3,086 ¥ millionEquity ratio 82.1%vs. prior year-end -5.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Outlook and shareholder returns
Annual Dividend Forecast¥0 → ¥0（0.0%）
Factors Behind Changes in Business Performance
The company received milestone revenue and an advance payment from 富士フイルム富山化学 in July 2026 and began sales of Telomelysin injection in August 2026.
Disclosure regarding the going concern assumption
Not applicable
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsBetween 1 October 2026 and 31 October 2026, some of the 13th, 14th and 16th Series Stock Acquisition Rights were exercised, and 112,000 common shares were issued. Total exercise proceeds were ¥83.552 million.
Depreciation and amortization225 Thousand yen
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End29,575,700 shares
Treasury Shares at Period-End27,643 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥527 million |
| Operating profit | ¥-1,104 million |
| Ordinary income | ¥-1,112 million |
| Profit attributable to owners of the parent | ¥-1,115 million |
| Net income per share | −¥38.01 |
| Equity ratio | End of the current fiscal period 82.1 / End of previous period 87.6 |
| Total assets | ¥3,752 million |
| Net assets | ¥3,086 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | 225 Thousand yen |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Between 1 October 2026 and 31 October 2026, some of the 13th, 14th and 16th Series Stock Acquisition Rights were exercised, and 112,000 common shares were issued. Total exercise proceeds were ¥83.552 million. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 29,575,700 shares |
| Treasury Shares at Period-End | 27,643 shares |
| Factors Behind Changes in Business Performance | The company received milestone revenue and an advance payment from 富士フイルム富山化学 in July 2026 and began sales of Telomelysin injection in August 2026. |
Items this document does not state (16)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidation
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company received milestone revenue and an advance payment from 富士フイルム富山化学 in July 2026 and began sales of Telomelysin injection in August 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.